Professor Bloom and his team, study the physiology of appetite control by gut hormones, including pancreatic polypeptide (PP), peptide YY (PYY), glucagon and glucagon-like peptide-1 (GLP-1). By understanding the mechanisms of appetite suppression and stimulation of energy expenditure by gut hormones, they are designing a treatment for obesity – the health challenge of the century.
In the Imperial CRF, the team’s latest studies have identified the physiology of PP and PYY’s actions. Using this information, a new analogue of PP, PP 1420 was designed. Its development from the pre-clinical phase to a Phase 1 ‘first time in humans’ study was funded by the Wellcome Trust via their Seeding Drug Discovery initiative. The Phase 1 trial was successfully conducted in the SJMC in October 2010. It showed that PP1420 is safe and well tolerated, and provided valuable pharmacokinetic data.
Prof Bloom has developed a new analogue of PYY, named Y242. This has been shown to achieve powerful suppression of food intake and can be given every week as a small injection. Y242 is currently undergoing Phase 1a first time in human trials to demonstrate its safety and tolerability, funded by the MRC Developmental Clinical Studies Scheme.
PI: Professor Sir Steve Bloom